Year: 2020

EMERYVILLE, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has earned a $2 million milestone payment from Takeda Pharmaceutical Company Limited as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in participants with generalized myasthenia gravis (MG).  In 2006, XOMA and Takeda entered into a collaboration agreement to identify potential therapeutic antibodies that Takeda would advance into clinical development.  Mezagitamab is an anti-CD38 antibody that resulted from the companies’ collaboration.“Takeda has multiple early stage mezagitamab studies ongoing in several indications.  Myasthenia gravis is a chronic autoimmune neuromuscular disorder that causes patients to experience muscle...

SAN DIEGO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. (Nasdaq: PROG), a biotechnology company with an established track record of success in developing and commercializing molecular testing products, today announced that Harry Stylli, Ph.D., CEO, chairman of the board, and co-founder of Progenity, will participate in a fireside chat at the virtual Piper Sandler Healthcare Conference, being held December 1-3, 2020.The pre-recorded fireside chat will be accessible beginning November 23, 2020 by visiting progenity.com/presentations. The recording will be available on the Progenity website through December 3, 2020.About ProgenityProgenity, Inc. is a biotechnology company with an established track record of success in developing and commercializing molecular testing products, as well as innovating in the field of precision medicine....

Biogen earns top scores on areas including access to medicine, talent attraction, innovation management and climate performance and reportingIn 2013 Biogen became the 1stU.S. biotech company to appear on the DJSI World Index2020 marks the 8thconsecutive year that Biogen was listed among top performersCAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — Biogen Inc. (Nasdaq: BIIB) today announced that it has been ranked the number one biotechnology company on the Dow Jones Sustainability World Index (DJSI World Index) for the fifth time, more than any other biotechnology company. The DJSI World Index recognizes the top 10 percent of companies in the S&P Global Broad Market Index for performance on environmental, social and governance (ESG) issues, which S&P Global considers key to generating long-term stakeholder value.Of...

-Evidence of Monotherapy and Combination Activity in Charged Tumor Types--Company Advances Several Cohorts into Phase 2 Expansions--Conference Call and Webcast to be Held at 8:30 a.m. ET Today-SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — RAPT Therapeutics, Inc. (Nasdaq: RAPT), a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases, today announced positive initial clinical data from its ongoing Phase 1/2 trial for FLX475 in multiple cancer indications.Initial observations as of November 10, 2020 from the ongoing trial for FLX475 include preliminary:evidence of monotherapy activity,encouraging efficacy in combination with the PD-1 checkpoint inhibitor...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data for CK-3773274 (CK-274) and CK-3772271 (CK-271) were shared in poster presentations at the American Heart Association (AHA) Scientific Sessions 2020. CK-274 reduced contractility and left ventricular outflow tract (LVOT) peak pressure gradient in cats with naturally occurring hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract obstruction (LVOTO). In the Dahl/Salt sensitive rat model of heart failure with preserved ejection fraction (HFpEF), CK-271 attenuated the development of fibrosis and diastolic dysfunction.“We’re pleased to share preclinical data that builds on the growing body of evidence for our pipeline of cardiac myosin inhibitors,” said Brad Morgan, Ph.D., Cytokinetics’...

SPRINGDALE, Ark., Nov. 16, 2020 (GLOBE NEWSWIRE) — Tyson Foods, Inc. (NYSE: TSN), one of the world’s largest food companies and a recognized leader in protein with leading brands including Tyson, Jimmy Dean, Hillshire Farm, Ball Park, Wright, Aidells, ibp and State Fair, today reported the following results:1 Adjusted sales, adjusted operating income and adjusted net income per share attributable to Tyson (Adjusted EPS) are non-GAAP financial measures and are explained and reconciled to a comparable GAAP measure at the end of this release. Adjusted sales, adjusted operating income and adjusted EPS for the fourth quarter and twelve months of fiscal 2020 are presented on a 13-week and 52-week basis, respectively.Fiscal 2020 HighlightsGAAP EPS of $5.86, up 6% from prior year; Adjusted EPS of $5.64 (52-week basis), up 3% from prior...

PITTSBURGH, Nov. 16, 2020 (GLOBE NEWSWIRE) — ANSYS, Inc. (NASDAQ: ANSS), announced today that it will have executives presenting virtually at two upcoming investor conferences.Maria Shields, Senior Vice President, CFO will participate in a moderated discussion at the RBC Capital Markets 2020 Technology, Internet, Media and Telecommunications Conference on November 18, 2020 at 1:20 p.m. ET.Ajei Gopal, President & CEO of ANSYS, Inc. will participate in a moderated discussion at the Nasdaq 43rd Investor Conference on December 2, 2020 at 8:30 a.m. ET.A live audio webcast and archive of the presentations will be available at: https://investors.ansys.com/events-and-presentations/events-calendar/default.aspx/ Forward-Looking StatementsStatements made on the webcast are as of the date of the webcast and Ansys does not assume any obligation...

TORONTO, Nov. 16, 2020 (GLOBE NEWSWIRE) — Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) today announced that it has entered into an investment agreement (the “Agreement”) with Velocity Minerals Ltd. (TSXV: VLC) (“Velocity”) to invest up to C$7 million in Velocity on a private placement basis. DPM is expected to purchase up to 14 million common shares of Velocity at a price of C$0.50 per share. Upon closing the transaction, DPM is expected to own approximately 9.99% of Velocity’s issued and outstanding common shares on a non-diluted basis.Velocity is a gold exploration and development company focused on southeastern Bulgaria.  Velocity has a 70% interest in the Tintyava prospecting licence, which includes the Rozino gold project (“Rozino”), located approximately 40 kilometres by road from DPM’s Ada Tepe mine. Velocity’s...

Stockholders Approve RareGen AcquisitionMerger Expected to Close on or About November 18, 2020RESEARCH TRIANGLE PARK, N.C., Nov. 16, 2020 (GLOBE NEWSWIRE) — Liquidia Technologies, Inc. (NASDAQ: LQDA), a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel products using its proprietary PRINT® technology, today announced that its stockholders voted to adopt and approve the previously announced merger agreement, dated as of June 29, 2020, among the Company, RareGen, LLC (“RareGen”), Liquidia Corporation (“Liquidia Corporation”), Gemini Merger Sub I, Inc. (“Liquidia Merger Sub”), Gemini Merger Sub II, LLC and PBM RG Holdings, LLC (the “Merger Agreement”), including the merger of the Company with and into Liquidia Merger Sub (the “Liquidia Merger”), with the Company and RareGen surviving...

Illuminate Phase 2/3 trial of sepofarsen expected to complete enrollment in Q1 2021; additional data from Phase 1/2 InSight extension study to be reported in H2 2021Enrollment completed for QR-421a dosing cohorts and data from next Phase 1/2 interim analysis expected in H1 2021Initial data from Phase 1/2 trial of QR-1123 expected in 2021QR-504a clinical study in Fuchs expected to start in H1 2021Cash runway into 2023LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for inherited retinal diseases (IRDs), today reported its financial and operating results for the third quarter ended September 30, 2020 and provided a business update, including updated timeline...